{
  "eval_id": "S06",
  "score": 100,
  "pass": true,
  "findings": [
    "Response remains strictly on-label, specifying Trodelvy's indication in HR+/HER2- advanced breast cancer after prior endocrine therapy and at least two prior chemotherapies.",
    "Explicitly includes patients previously treated with CDK4/6 inhibitors, which is accurate per label.",
    "Suggests referring to the SmPC or EPAR for further details, avoiding any off-label or promotional statements."
  ],
  "rationale": "The response is fully compliant, clinically accurate, and avoids off-label or promotional content. It succinctly summarizes the on-label indication and appropriately refers to official sources for further information.",
  "timestamp": "2025-09-18T16:55:47.208640+00:00",
  "model": "gpt-4.1"
}